United StatesÚltimas notícias

Sagtec Global (NASDAQ:SAGT) issued its financial outlook for fiscal year 2026, projecting total revenue of US$25.8 million.

GRI Bio (NASDAQ:GRI) received FDA Orphan Drug Designation for its idiopathic pulmonary fibrosis drug candidate, GRI-0621.

Bank of England Governor Andrew Bailey tells broadcasters energy prices remain above pre-war levels and that the the central bank needs to assess "how much damage has been done to the infrastructure for supplying energy" in the Middle East. "I think holding is the right position to be in at the moment." Bailey speaks in an interview following the BOE's decision to keep interest rates at 3.75% in a 7-2 vote.

IM Cannabis (NASDAQ:IMCC) announced on June 18, 2026, that it has entered into a non-binding letter of intent to sell its European-focused subsidiary, IMC Holdings, to Slil.com Holding.

Ed Yardeni of Yardeni Reseach says Federal Reserve Chairman Kevin Warsh "pretty much" committed to bringing inflation down to 2%. Yardeni talks about what Warsh will do now on "Bloomberg Surveillance."

The Allstate Corporation (NYSE:ALL) reported estimated catastrophe losses of $289 million, or $228 million after-tax, for the month of May.

Lennox (NYSE:LII) has executed a definitive agreement to acquire Heat Controller, a North American supplier of heating and cooling equipment.

President Donald Trump signed an interim deal to end the war with Iran and reopen the Strait of Hormuz, but some Republicans say the US is giving up too much. Laura Davison reports on how the deal came together and what comes next.

Centrus Energy (NYSE:LEU) and Oklo (NYSE:OKLO) announced a letter of intent for the supply of domestic HALEU to power up to five Aurora powerhouses over multiple years.

Beam Therapeutics (NASDAQ:BEAM) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BEAM-304.

Deluxe (NYSE:DLX) announced on June 18, 2026, that it has reached a definitive agreement to acquire Celero Commerce, a financial technology firm focused on payment solutions for small and medium-sized businesses, for $625 million.

Novocure (NASDAQ:NVCR) announced that its Phase 3 TRIDENT trial evaluating Tumor Treating Fields (TTFields) therapy for glioblastoma did not achieve a statistically significant improvement in overall survival.